These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23174745)

  • 1. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion.
    Goyal BR; Mehta AA
    Hum Exp Toxicol; 2013 Jun; 32(6):571-90. PubMed ID: 23174745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetic cardiomyopathy].
    Huang YQ; Wang X; Kong W
    Sheng Li Ke Xue Jin Zhan; 2010 Feb; 41(1):31-6. PubMed ID: 21417012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy.
    Frati G; Schirone L; Chimenti I; Yee D; Biondi-Zoccai G; Volpe M; Sciarretta S
    Cardiovasc Res; 2017 Mar; 113(4):378-388. PubMed ID: 28395009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diabetic cardiomyopathy: concept, heart function, and pathogenesis].
    Codinach Huix P; Freixa Pamias R
    An Med Interna; 2002 Jun; 19(6):313-20. PubMed ID: 12152393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy.
    Jellis C; Wright J; Kennedy D; Sacre J; Jenkins C; Haluska B; Martin J; Fenwick J; Marwick TH
    Circ Cardiovasc Imaging; 2011 Nov; 4(6):693-702. PubMed ID: 21946703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise Amaliorates Metabolic Disturbances and Oxidative Stress in Diabetic Cardiomyopathy: Possible Underlying Mechanisms.
    Mahmoud AM
    Adv Exp Med Biol; 2017; 999():207-230. PubMed ID: 29022265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.
    Huynh K; Bernardo BC; McMullen JR; Ritchie RH
    Pharmacol Ther; 2014 Jun; 142(3):375-415. PubMed ID: 24462787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.
    Jia G; Hill MA; Sowers JR
    Circ Res; 2018 Feb; 122(4):624-638. PubMed ID: 29449364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of diabetes on alteration of metabolism in cardiac myocytes: therapeutic implications.
    Kota SK; Kota SK; Jammula S; Panda S; Modi KD
    Diabetes Technol Ther; 2011 Nov; 13(11):1155-60. PubMed ID: 21751873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of cardiac dysfunction in diabetes mellitus.
    Dhalla NS; Pierce GN; Innes IR; Beamish RE
    Can J Cardiol; 1985; 1(4):263-81. PubMed ID: 3850773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updating experimental models of diabetic cardiomyopathy.
    Fuentes-Antrás J; Picatoste B; Gómez-Hernández A; Egido J; Tuñón J; Lorenzo Ó
    J Diabetes Res; 2015; 2015():656795. PubMed ID: 25973429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FT23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy.
    Tan SM; Zhang Y; Wang B; Tan CY; Zammit SC; Williams SJ; Krum H; Kelly DJ
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):650-6. PubMed ID: 22612418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The vulnerable myocardium. Diabetic cardiomyopathy.
    Bugger H; Bode C
    Hamostaseologie; 2015; 35(1):17-24. PubMed ID: 25408270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diabetic cardiomyopathy: pathophysiological mechanisms of structural and functional changes.].
    Slavíková J; Mistrová E; Dvoráková Chottová M
    Cesk Fysiol; 2016 Oct; 65(2):75-83. PubMed ID: 29489085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FT011, a new anti-fibrotic drug, attenuates fibrosis and chronic heart failure in experimental diabetic cardiomyopathy.
    Zhang Y; Edgley AJ; Cox AJ; Powell AK; Wang B; Kompa AR; Stapleton DI; Zammit SC; Williams SJ; Krum H; Gilbert RE; Kelly DJ
    Eur J Heart Fail; 2012 May; 14(5):549-62. PubMed ID: 22417655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics.
    Jakubik D; Fitas A; Eyileten C; Jarosz-Popek J; Nowak A; Czajka P; Wicik Z; Sourij H; Siller-Matula JM; De Rosa S; Postula M
    Cardiovasc Diabetol; 2021 Feb; 20(1):55. PubMed ID: 33639953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy.
    Li J; Ma W; Yue G; Tang Y; Kim IM; Weintraub NL; Wang X; Su H
    J Mol Cell Cardiol; 2017 Jan; 102():53-60. PubMed ID: 27913284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.
    Falcão-Pires I; Leite-Moreira AF
    Heart Fail Rev; 2012 May; 17(3):325-44. PubMed ID: 21626163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetic cardiovascular autonomic neuropathy: clinical implications.
    Karayannis G; Giamouzis G; Cokkinos DV; Skoularigis J; Triposkiadis F
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):747-65. PubMed ID: 22894631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of epigenetics and miRNA in diabetic cardiomyopathy.
    Asrih M; Steffens S
    Cardiovasc Pathol; 2013; 22(2):117-25. PubMed ID: 22951386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.